NDAINHALATIONAEROSOL, METERED
Approved
Apr 2016
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
1
Data completeness
7/8 — Comprehensive
BEVESPI AEROSPHERE (glycopyrrolate and formoterol fumarate) by AstraZeneca is fumarate. Approved for copd, asthma, chronic obstructive pulmonary disease. First approved in 2016.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BEVESPI AEROSPHERE is a combination inhaled maintenance therapy containing glycopyrrolate (long-acting anticholinergic) and formoterol fumarate (long-acting beta-2 agonist) approved by FDA in April 2016. It is indicated for chronic obstructive pulmonary disease (COPD) and asthma, delivered via metered-dose aerosol inhaler. The dual mechanism provides bronchodilation through M3 receptor antagonism in airway smooth muscle combined with beta-2 adrenergic stimulation, addressing multiple pathophysiologic pathways in obstructive airway disease.
$0.1BPart D
4.9 years to LOEMechanism of Action
fumarate. The mechanism of action described below for the individual components applies to BEVESPI AEROSPHERE. These drugs represent two different classes of medications (an anticholinergic, and a long-acting selective beta 2 -adrenoceptor agonist) that have different effects on clinical physiology…
Worked on BEVESPI AEROSPHERE at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.